Ariad (ARIA) Abstracts
Several data presentations will be made for Iclusig (Ponatinib) for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2.
Immunogen (IMGN) Abstracts
The focus will be on two products using ADC (antibody-drug conjugate ) technology: IMGN853 utilizing a folate-receptor alpha targeting antibody in a pharmacokinetics (PK) and clinical evidence study study for epithelial ovarian cancer (EOC) and solid tumors; and IMGN529 which contains a CD-37 targeting antibody in a dose finding Phase I study for treatment of NHL.
Pharmacyclics (PCYC) Abstracts
A initial Phase 3 study of IMBRUVICA as a single agent for CLL showing long term safety and efficacy and in combination with antibody targeting CD-20 in a Phase 1b/2 study.
Other oncology stocks to watch: AGIO, CELG, CLVS, EPZM, MDVN, PBYI, SGEN, XLRN
ASCO ’14 Preview from Adam Feuerstein: ABBV, GILD, PCYC.
Three Month Stock Performance ARIA, CLDX, IMGN, PCYC with IBB at $231.50, FBT at $75.71